Mustafa Güney

Mustafa Güney

Auto-generated profile, based on publicly available information

Mustafa Güney

Blood Center, Gülhane Training and Research Hospital, Ankara 06010, Türkiye

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 August 2024 in Clinical Oral Investigations
Verified
Journal Article
Closed access
PDF file
HAHanife Altınışık
Hanife Altınışık
HCHülya Erten Can
Hülya Erten Can
NANecibe Başaran Mutlu Ağardan
Necibe Başaran Mutlu Ağardan
NBNA Berkkan
NA Berkkan
MGMustafa Güney
Mustafa Güney

1 September 2019 in Ortadoğu Tıp Dergisi
Verified
Journal Article
Open access
ASAli Korhan Sig
Ali Korhan Sig
ÖÖÖzlem Öz-Sığ
Özlem Öz-Sığ
MGMustafa Güney
Mustafa Güney

6 June 2025 in Metabolites
Verified
Journal Article
Open access
PDF file
SSSelim Sayın
Selim Sayın
MYMurat Yıldırım
Murat Yıldırım
BEBatuhan Erdoğdu
Batuhan Erdoğdu
OKOzan Kaplan
Ozan Kaplan
EKEmine Koc
Emine Koc
MAMELTEM Ayli
MELTEM Ayli
Background: Including Chronic Myeloid Leukemia (CML) patients with deep molecular responses (MR4.5) and those with suboptimal responses provides valuable insights into treatment-associated metabolic changes. This study aimed to characterize the metabolomic alterations associated with CML and identify potential biomarkers for treatment response, particularly in patients achieving a deeper molecular response versus those with poorer responses. Methods: Plasma samples were collected from 51 chronic-phase CML patients and 24 healthy controls. CML patients were classified into two groups based on molecular responses: T1 (BCR-ABL1 IS ≤ 0.0032%) and T2 (BCR-ABL1 IS > 0.0032%, 1.5 included glutamate, hypoxanthine, and D-galactonic acid. In the T2 group, significant increases in malate and 5-aminoimidazole-4-carboxamide ribonucleotide were observed, reflecting disruptions in purine metabolism, the tricarboxylic acid cycle, and amino acid metabolism. The pathway enrichment analysis highlighted significant alterations in CML energy metabolism, nucleotide synthesis, and amino acid biosynthesis. Conclusions: CML patients exhibit pronounced metabolic changes, particularly in energy and nucleotide metabolism, which are linked to treatment response. These findings provide novel insights into CML biology and suggest potential biomarkers for monitoring treatment efficacy and predicting outcomes and therapeutic targets for improving treatment outcomes and overcoming tyrosine kinase inhibitor resistance.

17 January 2021 in Journal of Clinical Medicine of Kazakhstan
Verified
Journal Article
Open access
PDF file
ABAyfer Bakır
Ayfer Bakır
MKMuhammed Furkan Kürkçü
Muhammed Furkan Kürkçü
MGMustafa Guney
Mustafa Guney
FYFatime Yildiz
Fatime Yildiz
MYMehmet Tevfik Yavuz
Mehmet Tevfik Yavuz
Objective: Measles virus is an unsegmented, single-stranded and negative-polarized RNA virus belonging to Morbillivirus genus in Paramyxoviridae family in the order of Mononegavirales. This study aimed to evaluate measles antibody seropositivity proportions in different age groups from different geographical regions within three years. Material and methods: This retrospective study, IgM and IgG antibodies specific to measles were detected in serum samples with enzyme immunoassay method. Measles IgG antibody seroprevalence was calculated by correlating all data with demographic variables. Results: Median age of patients included in the study was 27 years and while 352 (44.4%) were male. Seropositivity rate of measles IgG antibody was 87.1%. Seropositivity in the age group of 0-18 was 77.7% (p = 0.002). IgG seropositivity rates were 82.8%, 88.8% and 90.7% between 2017 and 2019 respectively (p = 0.05). Seropositivity rate of IgM antibody in all cases was 11.1% and the highest rate was detected in the age group of 0-18 (13.5%) (p = 0.09). IgM antibody seropositivity rate was determined most in the winter months (23.8%) (p < 0.001). While measles IgM positivities were 10.6% and 21.1% in Turkish and foreign patients respectively IgG positivities were 86.9% and 92.3% (p = 0.32, p = 1.00 respectively). Measles IgG seropositivity was the highest in patients living in Aegean region (96.8%). Conclusions: In conclusion, measles IgG seropositivity was 87.1% in this study. This rate was lower in pediatric age group. Increasing regional seroprevalence studies may help enhancement efforts on vaccination program to reach and sustain high population immunity.

22 September 2025 in Metabolites
Verified
Journal Article
Open access
PDF file
MYMurat Yıldırım
Murat Yıldırım
BEBatuhan Erdoğdu
Batuhan Erdoğdu
SSSelim Sayın
Selim Sayın
OKOzan Kaplan
Ozan Kaplan
EKEmine Koc
Emine Koc
MAMELTEM Ayli
MELTEM Ayli
Background/Objectives: The differential diagnosis between primary polycythemia vera (PV) and secondary polycythemia (SP) presents significant clinical challenges owing to substantial phenotypic overlap. This investigation utilized untargeted metabolomic approaches to elucidate disease-specific metabolic perturbations and evaluate the metabolic consequences of cytoreductive therapeutic interventions. Methods: Plasma specimens obtained from PV patients (n = 40) and SP patients (n = 25) underwent comprehensive metabolomic profiling utilizing liquid chromatography–mass spectrometry (LC-MS) platforms. Multivariate statistical analyses, including principal component analysis (PCA), were employed in conjunction with pathway enrichment analyses to characterize disease-associated metabolic dysregulation. Additionally, receiving treatment (tPV) (n = 25) and not receiving treatment (ntPV) (n = 15) PV patients were compared to assess therapeutic metabolic effects. Results: Comprehensive metabolomic analysis identified 67 significantly altered metabolites between PV and SP patients, with 36 upregulated and 31 downregulated in PV. Key upregulated metabolites in PV included thyrotropin-releasing hormone, 3-sulfinoalanine, nicotinic acid adenine dinucleotide, and protoporphyrin IX, while 4-hydroxyretinoic acid and deoxyuridine were notably downregulated. Pathway enrichment analysis revealed disruptions in taurine, glutamate, nicotinate, and cysteine metabolism in PV. ntPV patients exhibited higher glucose and octanoyl-CoA levels compared to treated patients, indicating the normalization of glucose and fatty acid metabolism with cytoreductive therapy. ntPV was also associated with altered B-vitamin metabolism, including decreased nicotinic acid adenine dinucleotide and increased nicotinamide ribotide levels. Cross-comparison analysis revealed overlapping pathway enrichment in glutamate metabolism, nicotinate and nicotinamide metabolism, and cysteine metabolism between both comparisons. Conclusions: This study demonstrates that PV and SP exhibit fundamentally distinct metabolic signatures, providing novel insights into disease pathogenesis and potential diagnostic biomarkers. The identification of oxidative stress signatures, disrupted energy metabolism, and altered B-vitamin cofactor pathways distinguishes PV from SP at the molecular level. Cytoreductive therapy significantly normalizes metabolic dysregulation, particularly glucose and nucleotide metabolism, validating current therapeutic approaches while revealing broader systemic treatment effects. The metabolic signatures identified, particularly the combination of deoxyuridine, thyrotropin-releasing hormone, and oxidative stress metabolites, may serve as complementary diagnostic tools to traditional morphological and molecular approaches. These findings advance our understanding of myeloproliferative neoplasm pathophysiology and provide a foundation for developing metabolically targeted therapeutic strategies and precision medicine approaches in PV management.

29 November 2020 in Medical Laboratory Technology Journal
Verified
Journal Article
Open access
PDF file
ABAyfer Bakır
Ayfer Bakır
MGMustafa Guney
Mustafa Guney
Toxoplasmosis, despite its mild course in immunocompetent individuals, it may have a more severe course in immunosuppressed patients such as hematology and oncology patients. This study aimed to contribute to the importance of that issue by evaluating the seropositivity rates of Toxoplasma gondii (T. gondii) in Hematology and Oncology patients and sharing the data obtained. Serum samples sent from pediatric and adult Hematology/Oncology outpatient clinic to the Microbiology Laboratory between January 2017 and August 2019 were analysed using Architect Toxo IgG and IgM Reagent Kit with chemiluminescent microparticular enzyme immunoassay method on Architect system. A total of 673 patient samples belonging to 131 pediatric patients and 542 adult patients were analysed in the study. Median age of the study group was 29 (range: 0 - 83) and 53.5% of them were male. While T. gondii IgM positivity was 8% IgG positivity was 28.7%. T. gondii IgG seropositivities in male and female patients were 27.2% and 30.4% respectively (p = 0.44). T. gondii IgM seropositivities in pediatric and adult patients were 6.9% and 8.3% respectively and IgG seropositivities were 24.4% and 29.7% (p = 0.78 and p = 0.46 respectively). T. gondii IgM positivity was found as 8% and IgG positivity as 28.7% in the study group. In conclusion, data obtained from the study were in compliance with both domestic and foreign data and the highest rate of IgM and IgG seropositivity was found in patients with lymphoma.